文献速递淋巴瘤

首创HSP110抑制剂通过SYK磷酸化阻断弥漫性大B细胞淋巴瘤中的BCR激活

First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma.
PubMed 文献 · Leukemia · 2024-06-21

研究使用首创HSP110抑制剂处理活化B细胞样弥漫性大B细胞淋巴瘤(ABC-DLBCL)细胞系与体内模型,发现抑制剂降低细胞存活并减少BTK、SYK等BCR信号激酶磷酸化。HSP110与SYK存在相互作用并促进SYK磷酸化;HSP110抑制剂与PI3K抑制剂copanlisib联用协同降低SYK/BTK和AKT磷酸化,抑制细胞系异种移植瘤生长并大幅减少患者来源异种移植瘤。结论认为HSP110抑制剂通过调控BCR/TLR信号通路,是ABC-DLBCL患者的潜在候选药物。

要点

  • HSP110抑制剂在体外和体内降低多种ABC-DLBCL细胞系的存活。
  • HSP110抑制剂减少BCR信号激酶BTK和SYK的磷酸化。
  • HSP110与SYK相互作用并促进SYK磷酸化。

核心结论

  • HSP110抑制剂通过调控BCR/TLR信号通路,是ABC-DLBCL患者的潜在候选药物。

研究设计与样本

  • 研究使用首创HSP110抑制剂,在ABC-DLBCL细胞系体外与体内模型以及细胞系异种移植和患者来源异种移植中开展实验。

主要发现

  • HSP110抑制剂在体外和体内降低多种ABC-DLBCL细胞系的存活。
  • HSP110抑制剂减少BCR信号激酶(包括BTK和SYK)的磷酸化。
  • 研究鉴定出HSP110与SYK之间存在相互作用,并证明HSP110促进SYK磷酸化。
  • HSP110抑制剂与PI3K抑制剂copanlisib联用协同降低SYK/BTK和AKT磷酸化,导致细胞系异种移植瘤生长受抑,患者来源异种移植瘤大幅减少。

临床怎么用

  • 作者认为HSP110抑制剂是ABC-DLBCL患者的潜在候选药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is driven by aberrant activation of the B-cell receptor (BCR) and the TLR/MyD88 signaling pathways. The heat-shock protein HSP110 is a candidate for their regulation as it stabilizes MyD88. However, its role in overall BCR signaling remains unknown. Here, we used first-in-class HSP110 inhibitors to address this question. HSP110 inhibitors decreased the survival of several ABC-DLBCL cell lines in vitro and in vivo, and reduced the phosphorylation of BCR signaling kinases, including BTK and SYK. We identified an interaction between HSP110 and SYK and demonstrated that HSP110 promotes SYK phosphorylation. Finally, the combination of the HSP110 inhibitor with the PI3K inhibitor copanlisib decreases SYK/BTK and AKT phosphorylation synergistically, leading to suppression of tumor growth in cell line xenografts and strong reduction in patient-derived xenografts. In conclusion, by regulating the BCR/TLR signaling pathway, HSP110 inhibitors are potential drug candidates for ABC-DLBCL patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Gibouin VC, Durand M, Boudesco C, et al. First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma. Leukemia. 2024. PMID: 38906964. doi:10.1038/s41375-024-02302-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。